Use of olprinone, a phosphodiesterase III inhibitor, in an asthmatic patient

Authors: Hirota, K.; Kabara, S.; Hashimoto, H.; Ishihara, H.; Matsuki, A.

Source: Acta Anaesthesiologica Scandinavica, Volume 45, Number 4, April 2001 , pp. 510-512(3)

Publisher: Wiley-Blackwell

Buy & download fulltext article:


Price: $48.00 plus tax (Refund Policy)


Phosphodiesterase (PDE) III exists in airway smooth muscles. In addition, PDEIII inhibitors have been suggested to relax airway smooth muscle by increasing intracellular cAMP concentrations. We report a successful use of olprinone, a PDEIII inhibitor, for treatment of an asthmatic attack. A 15-year-old male patient treated with oral theophylline 400 mg· d−1 was anesthetized with propofol, fentanyl and ketamine for knee joint surgery. Immediately after tracheal intubation, an asthma attack occurred with peak airway pressure (Paw)>40 cmH2O. Thus, propofol 20 mg was additionally given to increase anesthetic depth, and Paw gradually decreased to 30 cmH2O. In addition, we started monitoring bronchial cross-sectional area using a superfine fiberoptic bronchoscopic method previously reported. However, as Paw did not further decrease for 30 min, olprinone was intravenously infused (10 μg · kg−1 · 10 min−1+0.3 μg · kg−1 · min−1, total 5 mg). Olprinone infusion rapidly decreased peak Paw from 30 cmH2O to 24 cmH2O and increased bronchial cross-sectional area by 50%. These findings suggest that olprinone produced bronchodilation.

Keywords: Olprinone; asthma; bronchodilation; phosphodiesterase III inhibitor

Document Type: Research Article


Publication date: April 1, 2001

Related content



Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page